Table 2—

Evolution over time of demographics, insulin sensitivity, β-cell function, and glucose tolerance in subjects with NGT who did or did not progress to IGT

First assessment
Second assessment
NonprogressorsProgressorsP valueNonprogressorsProgressorsP value
n (female/male)10 (7/3)6 (4/2)10 (7/3)6 (4/2)
Age (years)35.6 ± 7.739.2 ± 10.90.5942.1 ± 8.246.5 ± 10.70.48
Weight (kg)85.5 ± 11.986.1 ± 20.50.7089.6 ± 10.0100.8 ± 39.00.99
BMI (kg/m2)27.7 ± 3.229.3 ± 5.80.6629.2 ± 2.934.2 ± 11.40.23
Waist circumference (cm)97 ± 999 ± 160.74103 ± 7108 ± 290.59
Hip circumference (cm)111 ± 8111 ± 100.83109 ± 7115 ± 140.59
Waist-to-hip ratio0.88 ± 0.070.89 ± 0.110.450.95 ± 0.070.93 ± 0.140.45
Fasting glucose (mmol/l)5.17 ± 0.335.00 ± 0.280.364.94 ± 0.404.98 ± 0.480.87
Fasting insulin (pmol/l)60.3 ± 19.760.2 ± 35.60.4553.3 ± 19.297.8 ± 71.60.16
Adiponectin (μg/ml)11.9 ± 2.015.4 ± 3.00.3310.9 ± 1.511.4 ± 2.00.91
SI (× 10−5 min−1/pmol)5.8 ± 2.9 (5.2)5.1 ± 2.4 (4.6)0.555.6 ± 3.2 (4.8)4.5 ± 2.7 (3.7)0.42
AIRg (pmol/l)509 ± 342 (399)355 ± 231 (309)0.59452 ± 298 (372)267 ± 130 (244)0.16
DI (× 10−5 min−1)2,437 ± 1,232 (2,075)1,646 ± 888 (1,421)0.191,949 ± 824 (1,786)1,017 ± 511 (903)0.05
Sg (× 10−2 min−1)2.27 ± 0.361.63 ± 0.410.0092.00 ± 0.571.53 ± 0.470.10
GEZI (× 10−2 min−1)1.94 ± 0.381.36 ± 0.490.0511.73 ± 0.611.23 ± 0.520.10
Kg (%/min)2.08 ± 0.621.61 ± 0.450.081.73 ± 0.461.29 ± 0.280.03
2-h glucose (mmol/l)6.15 ± 0.866.34 ± 0.610.876.12 ± 0.888.75 ± 1.180.001
AUCG (mmol/l × min)197 ± 69207 ± 660.74224 ± 76496 ± 1010.001
  • Data are arithmetic means ± SD with geometric means where appropriate in parentheses. P values are for the comparison between progressors and nonprogressors at the same assessment.